ARTICLE | Product R&D
Opening doors in PML
How NIH and Neurimmune are collaborating and competing in PML
December 14, 2017 11:20 PM UTC
An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options, the results provide a rationale for a therapeutic alternative to NIH’s own early stage preventive vaccine.
Moreover, the paper, published in an October issue of Cell Reports, uncovered the mechanism by which the virus enters brain cells, a mystery that has counfounded the field...